|
Home > Conversation |
‘Genomics
may aid in development of personalised therapy’
Dr Kalyanasundaram Subramanian is the Chief Scientific Officer of
Strand Genomics, a leading player in India in the budding science
of genomics. It has partnerships in research with many world organisations
of repute. Dr Subramanian has research interests in modelling of disease
states, systems biology and predictive ADME and toxicology. Prior
to joining Strand, he was a senior Bio-Systems Engineer at Entelos
Inc, where he headed the collaborative R&D group for immunology
products. He has a PhD in Biomedical Engineering from John Hopkins
University, Baltimore, an MS in Chemical Engineering from State University
of New York, at Buffalo and B Tech in Chemical Engineering from Indian
Institute of Technology, Mumbai. In an exclusive interview with
R BabyManoj, he talks about the facets of genomics, as a potential
discipline in the area of pharmaceutical science, while sharing details
of his company and its products. Excerpts: |
|
|
